Swarmer R&D increased by 184.6% to $1.49M in Q1 2026 compared to the prior quarter.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $522.20K | $1.49M |
| QoQ Change | — | +184.6% |
| YoY Change | — | +184.6% |